Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924525 | 1.00 | LMNA (0.56) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL9855964 | 0.87 | LMNA (0.71) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL9855968 | 0.87 | LMNA (0.71) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL7108324 | 0.87 | LMNA (0.52) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL28249422 | 0.86 | LMNA (0.51) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL7109642 | 0.85 | NPC1 (0.44) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL7109645 | 0.85 | NPC1 (0.44) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| Isobutyl Cinnamate SCHEMBL28250183 | 0.85 | LMNA (0.50) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| SCHEMBL29010570 | 0.84 | LMNA (0.51) | LMNAAKR1B10AKR1B1KMT2AMEN1 | |
| Allyl Cinnamate SCHEMBL27652867 | 0.84 | APP (0.50) | LMNAAKR1B10AKR1B1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599937-B1 | For modulating gene expression in a hematopoietic cell | BEACON LABORATORIES, INC. | 2003-07-29 | — | — | US | claimed |
| EP-0973388-A4 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | BEACON LAB INC (US) | 2003-03-19 | — | — | EP | claimed |
| US-6124495-A | TREATING, PREVENTING OR AMELIORATING CANCER OR OTHER PROLIFERATIVE DISORDER; INCREASING HEMOGLOBIN CONTENT IN BLOOD; MODULATING AN IMMUNE RESPONSE; AMELIORATING THE EFFECTS OF A CYTOTOXIC AGENT; TREATING GASTROINTESTINAL DISORDERS | BEACON LABORATORIES, INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-0973388-A1 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | Beacon Laboratories, Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| US-5939455-A | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives | BEACON LABORATORIES, INC. (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998040078-A1 | THERAPEUTIC AUGMENTATION OF OXYALKYLENE DIESTERS AND BUTYRIC ACID DERIVATIVES | BEACON LABORATORIES, INC. (US) | 1998-09-17 | — | — | WO | claimed |
| WO-1998039965-A1 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | BEACON LABORATORIES, INC. (US) | 1998-09-17 | — | — | WO | claimed |
| US-6667341-B2 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders | BEACON LABORATORIES, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | BEACON LABORATORIES, INC, A DELAWARE CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-6599937-B1 | For modulating gene expression in a hematopoietic cell | BEACON LABORATORIES, INC. | 2003-07-29 | — | — | US | disclosed |
| US-6562995-B1 | Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having | BEACON LABORATORIES, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-0973388-A4 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | BEACON LAB INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | ERRANT GENE THERAPEUTICS, LLC | 2002-09-26 | — | — | US | disclosed |
| EP-1216986-A2 | Novel delta dicarbonyl compounds and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6124495-A | TREATING, PREVENTING OR AMELIORATING CANCER OR OTHER PROLIFERATIVE DISORDER; INCREASING HEMOGLOBIN CONTENT IN BLOOD; MODULATING AN IMMUNE RESPONSE; AMELIORATING THE EFFECTS OF A CYTOTOXIC AGENT; TREATING GASTROINTESTINAL DISORDERS | BEACON LABORATORIES, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0973388-A1 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | Beacon Laboratories, Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5939455-A | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives | BEACON LABORATORIES, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998040078-A1 | THERAPEUTIC AUGMENTATION OF OXYALKYLENE DIESTERS AND BUTYRIC ACID DERIVATIVES | BEACON LABORATORIES, INC. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998039965-A1 | UNSATURATED OXYALKYLENE ESTERS AND USES THEREOF | BEACON LABORATORIES, INC. (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171409-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | LMNA 2800/4885AKR1B10 213/4885AKR1B1 298/4885 |
| US-20020137775-A1 | Novel delta dicarbonyl compounds and methods for using the same | HCCS, CPS1, ACAA2 | LMNA 2800/4885AKR1B10 213/4885AKR1B1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.